We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+21.97%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.76B
AUM Growth
+$163M
Cap. Flow
-$58.5M
Cap. Flow %
-2.12%
Top 10 Hldgs %
29.44%
Holding
155
New
9
Increased
52
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$21.9M
2
EHC icon
Encompass Health
EHC
+$17.3M
3
ALLK
Allakos
ALLK
+$16.6M
4
ELAN icon
Elanco Animal Health
ELAN
+$13.2M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$9.27M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$26.1M
2
GILD icon
Gilead Sciences
GILD
+$25.9M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$24.1M
4
ACHC icon
Acadia Healthcare
ACHC
+$22.1M
5
NUVA
NuVasive, Inc.
NUVA
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 89.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
51
Assembly Biosciences
ASMB
$529M
$18.2M 0.66%
40,833
+3,333
+9% +$1.56M
INSM icon
52
Insmed
INSM
$28.6B
$18M 0.65%
890,000
+65,000
+8% +$1.47M
TBPH icon
53
Theravance Biopharma
TBPH
$877M
$18M 0.65%
550,000
-102,600
-16% -$2.8M
BIIB icon
54
Biogen
BIIB
$30.7B
$17.7M 0.64%
50,000
-3,000
-6% -$1.03M
ARNA
55
DELISTED
Arena Pharmaceuticals Inc
ARNA
$17.3M 0.62%
375,000
– –
ASND icon
56
Ascendis Pharma A/S
ASND
$16.8B
$17.3M 0.62%
243,500
– –
ALNY icon
57
Alnylam Pharmaceuticals
ALNY
$29.3B
$17.2M 0.62%
196,500
+23,000
+13% +$2.31M
BOLD
58
DELISTED
Audentes Therapeutics, Inc
BOLD
$16.8M 0.61%
425,025
-14,975
-3% -$558K
HRTX icon
59
Heron Therapeutics
HRTX
$92.9M
$16.6M 0.6%
525,000
– –
ANAB icon
60
AnaptysBio
ANAB
$1.68B
$16.5M 0.6%
165,000
+15,000
+10% +$1.24M
IMMU
61
DELISTED
Immunomedics Inc
IMMU
$16.1M 0.58%
775,000
+275,000
+55% +$6.51M
BPMC
62
DELISTED
Blueprint Medicines
BPMC
$15.6M 0.57%
200,000
+1,000
+0.5% +$69.5K
RARE icon
63
Ultragenyx Pharmaceutical
RARE
$2.55B
$15.3M 0.55%
200,000
– –
ECYT
64
DELISTED
Endocyte, Inc. Common Stock
ECYT
$15.1M 0.55%
850,000
+175,000
+26% +$3M
RARX
65
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$13.6M 0.49%
750,000
– –
RIGL icon
66
Rigel Pharmaceuticals
RIGL
$750M
$13.2M 0.48%
412,500
+17,500
+4% +$525K
XENT
67
DELISTED
Intersect ENT, Inc
XENT
$13.2M 0.48%
460,000
+50,000
+12% +$1.5M
EPZM
68
DELISTED
Epizyme, Inc
EPZM
$13.2M 0.48%
1,241,253
– –
ELAN icon
69
Elanco Animal Health
ELAN
$11.1B
$13.1M 0.47%
+375,000
New +$13.2M
ACRS icon
70
Aclaris Therapeutics
ACRS
$869M
$12.8M 0.46%
880,000
+24,000
+3% +$411K
ARGX icon
71
argenx
ARGX
$54.1B
$12.5M 0.45%
165,000
+36,250
+28% +$3.21M
MNTA
72
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$12.5M 0.45%
475,000
+22,500
+5% +$608K
GTHX
73
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$12.2M 0.44%
233,073
-66,927
-22% -$3.65M
BMRN icon
74
BioMarin Pharmaceuticals
BMRN
$12.4B
$12.1M 0.44%
125,000
– –
FOLD
75
DELISTED
Amicus Therapeutics
FOLD
$12.1M 0.44%
1,000,000
– –
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Rock Springs Capital Management held 155 positions worth $2.76B, up 6.3% from $2.6B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management's Q3 2018 filing shows 9 new, 52 increased, 20 reduced and 11 closed positions. Its largest new stake was Allakos: 405,000 shares worth $18.2M. The largest sale was AbbVie, an estimated $26.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier.

  • Rock Springs Capital Management's largest Q3 2018 buy was Allakos: 405,000 shares worth $18.2M.
  • Rock Springs Capital Management added most to Boston Scientific in Q3 2018, an estimated $21.9M increase.
  • Rock Springs Capital Management's biggest Q3 2018 reduction was AbbVie, cutting an estimated $26.1M.
  • Rock Springs Capital Management fully exited Gilead Sciences in Q3 2018, selling an estimated $25.9M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.76B portfolio in Q3 2018.
  • Rock Springs Capital Management opened 9 new positions and closed 11 in Q3 2018.
  • Rock Springs Capital Management's portfolio value rose 6.3% quarter-over-quarter to $2.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.